losartan has been researched along with eplerenone in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (45.00) | 29.6817 |
| 2010's | 10 (50.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Fakouhi, K; He, W; Krause, S; Krum, H; Nolly, H; Roniker, B; Workman, D | 1 |
| Funder, JW; Mardini, M; Mihailidou, AS; Raison, M | 1 |
| Weber, MA | 1 |
| Flack, JM; Garthwaite, S; Kleiman, JH; Krause, SL; Oparil, S; Pratt, JH; Roniker, B; Saunders, E; Workman, D; Yang, Y | 1 |
| Ben-Yehuda, O | 1 |
| Aviram, M; Coleman, R; Hamoud, S; Hayek, T; Kaplan, M; Keidar, S; Pavlotzky, E | 1 |
| Davidson, RC; Krause, SL; MacDonald, TM; Patrick, JL; Roniker, B; Ruilope, LM; Weinberger, MH; White, WB | 1 |
| Gabor, A; Leenen, FH | 1 |
| Adamson, GE; Brandish, PE; Chen, H; Flores, OA; Forest, TW; Gatto, NT; Hershey, JC; Ma, BK; Molon-Noblot, S; Szczerba, P; Zwierzynski, I | 1 |
| Boulaksil, M; de Bakker, JM; Engelen, MA; Hauer, RN; Herold, E; Houtman, MJ; Jansen, JA; Joles, JA; Noorman, M; Stein, M; van Rijen, HV; van Veen, TA | 1 |
| Fujimoto, S; Fukuda, A; Iwatsubo, S; Kawachi, H; Kitamura, K | 1 |
| Chayama, K; Fujii, Y; Fujimura, N; Hata, T; Hidaka, T; Higashi, Y; Idei, N; Iwamoto, Y; Kato, H; Kihara, Y; Liao, JK; Maruhashi, T; Mikami, S; Noma, K; Soga, J | 1 |
| Cassis, LA; Daugherty, A; Gong, MC; Guo, Z; Liu, S; Pearson, KJ; Xie, Z | 1 |
| Bartelds, B; Berger, RM; Borgdorff, MA; Dickinson, MG; Steendijk, P | 1 |
| Conte, D; Minas, JN; Nishiyama, A; Ortiz, RM; Thorwald, MA; Vázquez-Medina, JP | 1 |
| Arias, SCA; Breyer, MD; Fanelli, C; Fujihara, CK; Jadhav, PK; Kowala, MC; Krieger, JE; Malheiros, DM; Montrose-Rafizadeh, C; Rodrigues, MV; Sena, CR; Zatz, R | 1 |
| Balogh, DB; Fekete, A; Genovese, F; Hodrea, J; Hosszu, A; Koszegi, S; Lakat, T; Lenart, L; Molnar, A; Sparding, N; Szabo, AJ; Szkibinszkij, E; Vannay, A; Wagner, L | 1 |
| Bourke, JP; Bueser, T; Quinlivan, R | 1 |
| Dabertrand, F; Ferris, HR; Greenstein, AS; Harraz, OF; Hill-Eubanks, DC; Koide, M; Longden, TA; Nelson, MT; Wellman, GC | 1 |
3 review(s) available for losartan and eplerenone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Clinical implications of aldosterone blockade.
Topics: Aldosterone; Antihypertensive Agents; Black People; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Eplerenone; Humans; Hypertension; Kidney Diseases; Losartan; Mineralocorticoid Receptor Antagonists; Potassium; Renin-Angiotensin System; Spironolactone | 2002 |
Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy.
Topics: Adolescent; Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cardiomyopathies; Cardiomyopathy, Dilated; Cardiovascular Agents; Child; Disease Progression; Eplerenone; Human Growth Hormone; Humans; Lisinopril; Losartan; Male; Muscular Dystrophy, Duchenne; Non-Randomized Controlled Trials as Topic; Perindopril; Placebos; Randomized Controlled Trials as Topic; Stroke Volume; Ubiquinone; Young Adult | 2018 |
4 trial(s) available for losartan and eplerenone
| Article | Year |
|---|---|
Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients.
Topics: Abdominal Pain; Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Eplerenone; Female; Headache; Heart Rate; Humans; Hypertension; Irbesartan; Losartan; Male; Middle Aged; Patient Dropouts; Renin-Angiotensin System; Spironolactone; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients.
Topics: Adult; Aldosterone; Analysis of Variance; Angiotensin Receptor Antagonists; Antihypertensive Agents; Black People; Blood Pressure; Double-Blind Method; Eplerenone; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Renin; Renin-Angiotensin System; Spironolactone; Treatment Outcome; White People | 2003 |
Effects of eplerenone versus losartan in patients with low-renin hypertension.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Double-Blind Method; Eplerenone; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Renin; Spironolactone | 2005 |
Mineralocorticoid receptor blocker eplerenone improves endothelial function and inhibits Rho-associated kinase activity in patients with hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Cell Movement; Endothelium, Vascular; Eplerenone; Female; Humans; Hypertension; Leukocytes; Losartan; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Nifedipine; Nitroglycerin; rho-Associated Kinases; Spironolactone; Stem Cells; Vascular Endothelial Growth Factor A; Vasodilation | 2012 |
13 other study(ies) available for losartan and eplerenone
| Article | Year |
|---|---|
Mineralocorticoid and angiotensin receptor antagonism during hyperaldosteronemia.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Eplerenone; Heart Ventricles; Hyperaldosteronism; Losartan; Magnesium; Male; Membrane Potentials; Mineralocorticoid Receptor Antagonists; Patch-Clamp Techniques; Potassium; Rabbits; Sodium; Sodium-Potassium-Exchanging ATPase; Spironolactone; Ventricular Function | 2002 |
Hypertension, angiotensin II, aldosterone, and race.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Antihypertensive Agents; Black People; Eplerenone; Humans; Hypertension; Losartan; Mineralocorticoid Receptor Antagonists; Renin; Renin-Angiotensin System; Spironolactone; Treatment Outcome; White People | 2003 |
Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Aortic Diseases; Apolipoproteins E; Arteriosclerosis; Cell Line; Enzyme Induction; Eplerenone; Hormone Antagonists; Humans; Lipid Peroxidation; Lipoproteins, LDL; Losartan; Macrophages, Peritoneal; Membrane Proteins; Mice; Mice, Knockout; Mineralocorticoid Receptor Antagonists; NADPH Oxidases; Oxidative Stress; Peptidyl-Dipeptidase A; Phosphoproteins; Protein Transport; Ramipril; Receptor, Angiotensin, Type 1; Receptors, Mineralocorticoid; RNA, Messenger; Spironolactone; Superoxides | 2004 |
Mechanisms in the PVN mediating local and central sodium-induced hypertension in Wistar rats.
Topics: Aldosterone; Amiloride; Angiotensins; Animals; Antihypertensive Agents; Blood Pressure; Cardiotonic Agents; Cerebrospinal Fluid; Diuretics; Dose-Response Relationship, Drug; Eplerenone; Heart Rate; Hypertension; Injections, Intraventricular; Losartan; Ouabain; Paraventricular Hypothalamic Nucleus; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptors, Mineralocorticoid; Sodium; Spironolactone | 2009 |
Eplerenone decreases inflammatory foci in spontaneously hypertensive rat hearts with minimal effects on blood pressure.
Topics: Animals; Blood Pressure; Eplerenone; Heart; Hypertension; Losartan; Male; Rats; Rats, Inbred SHR; Sodium Chloride, Dietary; Spironolactone | 2009 |
Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model.
Topics: Age Factors; Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Arrhythmias, Cardiac; Blood Pressure; Cardiac Pacing, Artificial; Cell Communication; Cellular Senescence; Connexin 43; Disease Models, Animal; Echocardiography, Doppler; Electrocardiography; Epicardial Mapping; Eplerenone; Female; Fibrosis; Heart Conduction System; Heart Diseases; Losartan; Mice; Mice, Inbred C57BL; Mineralocorticoid Receptor Antagonists; Myocardium; Renin-Angiotensin System; Spironolactone; Ventricular Function, Left; Ventricular Function, Right | 2010 |
Effects of mineralocorticoid and angiotensin II receptor blockers on proteinuria and glomerular podocyte protein expression in a model of minimal change nephrotic syndrome.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Disease Models, Animal; Eplerenone; Fluorescent Antibody Technique; Intracellular Signaling Peptides and Proteins; Losartan; Male; Membrane Proteins; Mineralocorticoid Receptor Antagonists; Nephrosis, Lipoid; Podocytes; Proteinuria; Puromycin Aminonucleoside; Rats; Rats, Sprague-Dawley; Sialoglycoproteins; Spironolactone; Time Factors | 2010 |
Mineralocorticoid receptor agonists induce mouse aortic aneurysm formation and rupture in the presence of high salt.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; Aortic Aneurysm, Abdominal; Aortic Aneurysm, Thoracic; Aortic Rupture; Apoptosis; Blood Pressure; Desoxycorticosterone; Disease Models, Animal; Elastin; Enalapril; Eplerenone; Losartan; Male; Mice; Mice, Inbred C57BL; Mineralocorticoid Receptor Antagonists; Muscle, Smooth, Vascular; Oxidative Stress; Receptors, Mineralocorticoid; Sodium Chloride, Dietary; Spironolactone; Time Factors | 2013 |
A cornerstone of heart failure treatment is not effective in experimental right ventricular failure.
Topics: Animals; Disease Models, Animal; Drug Therapy, Combination; Eplerenone; Heart Failure; Losartan; Male; Random Allocation; Rats; Rats, Wistar; Spironolactone; Treatment Outcome; Ventricular Dysfunction, Right | 2013 |
Angiotensin and mineralocorticoid receptor antagonism attenuates cardiac oxidative stress in angiotensin II-infused rats.
Topics: Adrenal Glands; Aldehydes; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Blood Pressure; Disease Models, Animal; Drug Therapy, Combination; Eplerenone; Heart Diseases; Hypertension; Lipid Peroxidation; Losartan; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Oxidative Stress; Rats, Sprague-Dawley; Renin-Angiotensin System; Signal Transduction; Spironolactone; Time Factors; Tyrosine | 2015 |
A Novel Aldosterone Antagonist Limits Renal Injury in 5/6 Nephrectomy.
Topics: Albuminuria; Aldosterone; Animals; Blood Pressure; Eplerenone; Losartan; Mineralocorticoid Receptor Antagonists; Nephrectomy; Rats, Wistar; Renal Insufficiency, Chronic; Renin; Treatment Outcome | 2017 |
RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Cell Line; Connective Tissue Growth Factor; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Epithelial Cells; Eplerenone; Fibroblasts; Fibrosis; Humans; Kidney; Losartan; Male; Mannitol; Mineralocorticoid Receptor Antagonists; Proto-Oncogene Proteins c-sis; Ramipril; Rats, Wistar; Renin-Angiotensin System; Spironolactone | 2019 |
Differential restoration of functional hyperemia by antihypertensive drug classes in hypertension-related cerebral small vessel disease.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Cerebral Small Vessel Diseases; Cerebrovascular Circulation; Dementia, Vascular; Disease Models, Animal; Drug Therapy, Combination; Eplerenone; Heart Disease Risk Factors; Humans; Hyperemia; Hypertension; Losartan; Male; Mice; Microvessels; Potassium Channels, Inwardly Rectifying; Renin-Angiotensin System | 2021 |